Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

Author's Avatar
Sep 22, 2018
Article's Main Image

Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression

PR Newswire